Clinical Neurology and Neurosurgery
Volume 112, Issue 7 , Pages 583-591 , September 2010

Overlapping and distinct mechanisms of action of multiple sclerosis therapies

  • J.J. Graber

      Affiliations

    • Department of Neurology, New York University School of Medicine, New York, NY, United States
    • Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
    • Corresponding Author InformationCorresponding author at: Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Tel.: +1 443 414 7861.
    • ,
  • C.A. McGraw

      Affiliations

    • Department of Neurology, Albert Einstein School of Medicine, Bronx, NY, United States
    • These authors contributed equally to this report.
    • ,
  • D. Kimbrough

      Affiliations

    • Department of Neurology, New York University School of Medicine, New York, NY, United States
    • These authors contributed equally to this report.
    • ,
  • S. Dhib-Jalbut

      Affiliations

    • Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ, United States
    • 97 Paterson Street, Room 205, New Brunswick, NJ, United States. Tel.: +1 732 235 7732.

Received 3 February 2010 ,Revised 27 April 2010 ,Accepted 4 May 2010.

References 

  1. Graber JJ, Dhib-Jalbut S. Protective autoimmunity in the nervous system. Pharmacol Ther. 2009;121:147–159
  2. Ransahoff RM. Cellular responses to interferons and other cytokines: the JAK-STAT paradigm. N Engl J Med. 1998;338:616–618
  3. Schweikert A, Kremer M, Ringel F, Liebig T, Duyster J, Stuve O, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2009;66:403–406
  4. Ozenci V, Kouwenhoven M, Teleshova N, et al. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol. 2000;108:236–243
  5. Sega S, Wraber B, Mesec A, et al. IFN-beta-1a and IFN-beta-1b have different patterns of influence on cytokines. Clin Neurol Neurosurg. 2004;106:255–258
  6. Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β. Ann Neurol. 2009;65:499–509
  7. Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S. IFN-β1a inihibits the secretion of Th17-polarizing cytokine in human dendritic cells via TLR7 upregulation. J Immunol. 2009;182:3928–3936
  8. Nicolleti F, et al. Circulating serum levels of IL-1Rα in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine. 1996;8:395–400
  9. Comabella M, Julia E, Tintore M, et al. Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interluekin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. J Neurol. 2008;255:1136–1141
  10. Sharief MK, Noori MA, Zoukos Y. Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-beta therapy. J Neuroimmunol. 2002;129:224–231
  11. Hallal-Longo DE, Miradnola SR, Oliviera EC, et al. Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-beta. J Interferon Cytokine Res. 2007;27:865–873
  12. de Andres C, Aristimuno C, de Las Heras V, et al. Interferon beta-1a therapy enhances CD4+ regulatory T cell function. J Neuroimmunol. 2007;182:204–211
  13. Korporal M, Haas J, Balint B, et al. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naice regulatory T cells. Arch Neurol. 2008;65:1434–1439
  14. Vandenbark AA, Huan J, Agotsch M, La Tocha D, Goelz S, Offner H, et al. Interferon-beta-1a treatment increases CD56(bright) natural killer cells and CD4+ CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol. 2009;215:125–128
  15. Graber JJ, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut S. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol. 2007;185:168–174
  16. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune deviation. J Neuroimmunol. 1998;92:113–121
  17. Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA. 2000;97:7452–7457
  18. Chen M, Conway K, Johnson KP, Martin R, Dhib-Jalbut S. Sustained immunological effect of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci. 2002;201:71–77
  19. Rieks M, Hoffmann V, Aktas O, Juschka M, Spitzer I, Brune N, et al. Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate. Eur Neurol. 2003;50:200–206
  20. Wiesemann E, Klatt J, Wenzel C, Heidenreich F, Windhagen A. Correlation of serum IL-13 and IL-5 levels with clinical response to glatiramer acetate in patients with multiple sclerosis. Clin Exp Immunol. 2003;133:454–460
  21. Valenzuela RM, Costello K, Chen M, Said A, Johnson K, Dhib-Jalbut S. Clinical response to glatiramer acetate correlates with modulation of IFN-γ and IL-4 expression in multiple sclerosis. Mult Scler. 2007;13:754–762
  22. Hestvik AL, Skorstad G, Price DA, Vartdal F, Holmoy T. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in cerebrospinal fluid. Mult Scler. 2008;14:749–758
  23. Vieira PL, Heysteck HC, Wormmeester J, Wierenga EA, Kapsenberg ML. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol. 2003;170:4483–4488
  24. Weber MS, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007;13:935–943
  25. Chen C, Liu X, Wan B, Zhang JZ. Regulatory properties of copolymer 1 in Th17 differentiation by altering STAT3 phosphorylation. J Immunol. 2009;183:246–253
  26. Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci USA. 1999;96:634–639
  27. Allie R, Hu L, Mullen KM, Dhib-Jalbut S, Calabresi PA. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch Neurol. 2005;62:889–894
  28. Ledeboer A, Breve JJ, Poole S, Tilders FJ, Van Dam AM. Interleukin-10, interleukin-4 and transforming growth factor-beta differentially regulate lipopolysaccharide-induced producing of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia. 2000;30:134–142
  29. Sanna A, Fois ML, Arru G, Huang YM, Link H, Pugliatti M, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol. 2006;143:357–362
  30. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-1 through activation of transcription factor FoxP3. Proc Natl Acad Sci USA. 2005;102:6454–6499
  31. Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis. J Clin Invest. 2002;109:641–649
  32. Ratts RB, Lovett-Racke AE, Choy J, et al. CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate. J Neuroimmunol. 2006;178:117–129
  33. Farina C, Bergh F, Albrecht H, et al. Treatment of multiple sclerosis with Copaxone (COP): elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain. 2001;124:705–719
  34. Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol. 2006;176:7119–7129
  35. Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, Karandikar NJ. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J Neuroimmunol. 2006;180:159–171
  36. Putheti P, Soderstrom M, Link H, Yuang YM. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol. 2003;144:125–131
  37. Dressel A, Vogelgesang A, Brinkmeier H, Mader M, Weber F. Glatiramer acetate specific human CD8+ T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment. J Neuroimmunol. 2006;181:133–140
  38. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA. 2003;100:14157–14162
  39. Ziemmsen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain. 2002;125:2381–2391
  40. Ziemmsen T, Schneider H. Presence of glatiramer acetate (GA)-specific T cells in the cerebrospinal fluid of GA-treated MS patients and GA-T cell transferred EAE mice producing Th2 cytokines and neurotrophic factors. Neurology. 2007;68:A314–A315[abstract]
  41. Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci. 2003;215:37–44
  42. Maier K, Kuhnert AV, Taheri N, et al. Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol. 2006;169:1353–1364
  43. Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59:743–747
  44. del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008;65:1596–1603
  45. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol. 2009;16:528–536
  46. Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63:1383–1387
  47. Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC. α4 integrin antagonism with natalizumab: effects and adverse effects. J Neurol. 2008;255(Suppl 6):58–65
  48. Kivisakk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009;72:1922–1930
  49. Tubridy N, Behan PO, Capildeo R, Forbes R, Hawkins CP, Hughes RA, et al. The effect of anti-alpha-4 integrin antibody on brain lesion activity in MS: the UK Antegren Study Group. Neurology. 1999;53:466–472
  50. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70:1150–1151
  51. Miller DH, Jhan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. NEJM. 2003;348:15–23
  52. O’Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, et al. Randomized multicenter trail of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004;62:2038–2043
  53. Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, et al. Immunologic and clinical status 14 months after cessation of natalizumab therapy. Neurology. 2009;72:396–401
  54. Gbadamosi J, Buhmann C, Tessmer W, Moench A, Haag F, Heesen C. Effects of mitoxantrone on multiple sclerosis patients’ lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol. 2003;49:137–141
  55. Putzki N, Kumar M, Kreuzfelder E, Grosse-Wilder H, Diener HC, Limmroth V. Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. Eur Neurol. 2009;61:27–32
  56. Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stuve O, et al. Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vivo. J Immunol. 2005;168:128–137
  57. Angelucci F, Batocchi AP, Caggiula M, Frisullo G, Patanella K, Sancricca C, et al. In vivo effects of mitoxantrone and on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients. Neuroimmunomodulation. 2006;13:76–81
  58. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol. 1997;41:669–674
  59. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology. 1997;49:1111–1116
  60. Calabresi PA, Prat A, Biernacki K, Rollins J, Antel JP. T lymphocytes conditioned with interferon-beta induce membrane and soluble VCAM on human brain endothelial cells. J Neuroimmunol. 2001;115:161–167
  61. Graber JJ, Zhan M, Ford D, et al. Interferon-beta induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroimmunol. 2005;161:169–176
  62. Muraro PA, Leist T, Bielekova B, McFarland HF. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol. 2000;111:186–194
  63. Soilu-Hanninen M, Salmi A, Salonen R. Interferon-beta downregulates expression of VLA-4 antigen and antagonizes interferon-gamma-induced expression of HLA-DQ on human peripheral blood monocytes. J Neuroimmunol. 1995;60:99–106
  64. Soilu-Hanninen M, Laaksonen M, Hanninen A, et al. Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS. J Neuroimmunol. 2005;108:236–243
  65. Prat A, Biernacki K, Antel JP. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon-beta and copolymer-1. J Autoimmun. 2005;24:119–124
  66. Zang YC, Halder JB, Samanta AK, et al. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol. 2001;112:174–180
  67. Lund BT, Ashikian N, Ta HQ, et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol. 2004;155:161–171
  68. Vallittu AM, Saraste M, Airas L. CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. Neurol Res. 2007;29:763–766
  69. Cepok S, Schreiber H, Hoffman S, et al. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol. 2009;66:1216–1223
  70. Stuve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol. 1996;40:853–863
  71. Leppert D, Waubant E, Burk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol. 1996;40:846–852
  72. Galboiz N, Shapiro S, Lahat N, et al. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to response to interferonbeta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol. 2001;50:443–451
  73. Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, et al. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology. 2003;60:52–57
  74. Garcia-Montojo M, Dominguez-Mozo MI, de las Heras V, Bartolome M, Garcia-Martinez A, Arroyo R, et al. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow up study. Eur J Neurol. 2010;17:470–478
  75. Niemela J, Ifergan I, Yegutkin GG, Jalkanen S, Prat A, Airas L. IFN-β regulates CD73 and adenosine expression at the blood-brain barrier. Eur J Immunol. 2008;38:2718–2726
  76. Li QQ, Bever CT. Glatiramer acetate blocks interleukin-1-dependent nuclear factor-kappaβ activation and RANTES expression in human U251 MG astroglial cells. Brain Res Mol Brain Res. 2001;87:48–60
  77. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest. 1990;94:1722–1728
  78. Bochner BS, Luscinskas FW, Gimbrone MA, et al. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cells adhesion molecules. J Exp Med. 1991;173:1553–1557
  79. Hemler ME, Elices MJ, Parker C, Takada Y. Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol Rev. 1990;114:45–65
  80. Rice G, Hartung H, Calabresi P. Anti-α4 integrin therapy for multiple sclerosis. Neurology. 2005;64:1336–1342
  81. Burkly LC, Jakubowski A, Newman BM, Rosa MD, Chi-Rosso G, Lobb RR. Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur J Immunol. 1991;21:2871–2875
  82. Damle NK, Aruffo A. Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+ T lymphocytes. Proc Natl Acad Sci USA. 1991;88:6403–6407
  83. Madri JA, Graesser D, Haas T. The roles of adhesion molecules and proteinases in lymphocyte transendothelial migration. Biochem Cell Biol. 1996;74:749–757
  84. Barry ST, Ludbrook SB, Murrison E, Horgan CM. Analysis of the alpha4beta1 integrin-osteopontin interaction. Exp Cell Res. 2000;258:342–351
  85. Chan PY, Aruffo A. VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J Biol Chem. 1993;268:24655–24664
  86. Li Z, Calzada MJ, Sipes JM, Cashel JA, Krutzsch HC, Annis DS, et al. Interactions of thrombospondins with α4β1 integrin and CD47 differntially module T cell behavior. J Cell Biol. 2002;157(3):509–519
  87. Kopadze T, Dehmel T, Hartung HP, Stuve O, Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol. 2006;63:1572–1578
  88. Weilbach FX, Chan A, Toyka KV, Gold R. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2004;135:49–55
  89. Ghandi KS, McKay FC, Schibeci SD, Arthur JW, Heard RN, Stewart GJ, et al. BAFF is a biological response marker to IFN-β treatment in multiple sclerosis. J Interferon Cytokine Res. 2008;28:529–540
  90. Kala M, Rhodes SN, Piao Wh , Shi FD, Campagnolo DI, Vollmer TL. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol. 2009;[Epub ahead of print]
  91. Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol. 2001;115:152–160
  92. Alter A, Duddy M, Hebert S, et al. Determinants of human B cell migration across brain endothelial cells. J Immunol. 2003;170:4497–4505
  93. Carrasco YR, Batista FD. B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 and VCAM-1. EMBO J. 2006;25:889–899
  94. Mauch E, Kornhuber HH, Krapf H, et al. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatr Clin Neurosci. 1992;242:96–102
  95. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol. 2004;139:152–158
  96. Genc K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997;99:2664–2671
  97. Giorelli M, Livrea P, Defazio G, et al. IFN-beta1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms. J Interferon Cytokine Res. 2001;21:809–812
  98. Kawanokuchi J, Mizuno T, Kato H, et al. Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology. 2004;46:734–742
  99. Marckmann S, Wiesemann E, Hilse R, et al. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis. Clin Exp Immunol. 2004;138:499–506
  100. Schreiner B, Mitsdoerffer M, Kieseier BC, et al. Interferon-beta enhances monocytes and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol. 2004;155:172–182
  101. Huynh HK, Oger J, Borovini-Zis K. Interferon-beta downregulates interferon-gamma-induced class II MHC expression and morphological changes in primary cultures of human brain microvascular endothelial cells. J Neuroimmunol. 1995;60:63–73
  102. Hussein Y, Sanna A, Soderstrom M, Link H, Huang YM. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol. 2001;121:102–110
  103. Fridkis-Hareli M, Neveu JM, Robinson RA, Lane WS, et al. Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol. 1999;162:4697–4704
  104. Weber MS, et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004;127:1370–1378
  105. Kim HJ, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004;172:7144–7153
  106. Liu J, Johnson TV, Lin J, Ramirez SH, Bronich TK, Caplan S, et al. T cell independent mechanism for copolymer-1-induced neuroprotection. Eur J Immunol. 2007;37:3143–3154
  107. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA. 2009;106:4355–4359
  108. Watson CM, Davison AN, Baker D, O’Neill JK, Turk JL. Suppression of demyelination by mitoxantrone. Int J Immunopharm. 1991;13:922–930
  109. Sand KL, Knudsen E, Rolin J, Al-Falahi Y, Maghazachi AA. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell Mol Life Sci. 2009;66:1446–1456
  110. Jin S, Kawanokuchi J, Mizuno T, et al. Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res. 2007;1179:140–146
  111. Tumani H, Uttner I. Influences on congition by immunosuppression and immunomodulation in multiple sclerosis. J Neurol. 2007;254(S1):S69–S72
  112. Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP for the Copaxone Study Group. Congitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci. 2007;15:57–63
  113. Patti F, Amato MP, Bastianello S, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing remitting multiple sclerosis. Mult Scler. 2010;16:68–77
  114. Freedman MS, Cohen B, Dhib-Jalbut S, et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin. 2009;25:2459–2470
  115. Ruiz-Pena JL, Duque P, Izquierdo G. Optimization of treatment with interferon beta in multiple sclerosis: usefulness of automatic system application criteria. BMC Neurol. 2008;8:3
  116. Freedman MS, Forrestal FG. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study. Mult Scler. 2008;14:1234–1241
  117. Gajofatto A, Bacchetti P, Grimes B, High A, Waudant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler. 2009;15:50–58
  118. Fox EJ, Vartanian TK, Zamvil SS. The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist. 2007;13:355–362
  119. Deisenhammer F. Neutralizing antibodies to interferon-β and other immunological treatments for multiple sclerosis. CNS Drugs. 2009;23:379–396
  120. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology. 2005;65:40–47
  121. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology. 2005;65:48–55
  122. Kracke A, Von Wussow P, Al-Masri AN, et al. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology. 2000;54:193–199
  123. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology. 2008;70:1119–1127
  124. Salama HH, Hong J, Zang Y, et al. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain. 2003;126:2638–2647
  125. Teitelbaum D, Brenner T, Abramsky O, et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler. 2003;9:592–599
  126. Blanchette F. Clinical significance of glatiramer acetate antibodies. Mult Scler. 2007;13(S1):S28–S35
  127. Lublin FD, Cutter GR, Elfont R. A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate in patients with relapsing MS. Neurology. 2001;56:A148
  128. Dhib-Jalbut S, Chen M, Henschel K, Ford D, Costello K, Panitch H. Effect of combined IFN-β-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler. 2002;8:485–491
  129. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–923
  130. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72:806–812
  131. Multiple Sclerosis Therapy Consensus Group , Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung P, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255:1449–1463
  132. Le Page E, Edan G. Long-term experience with induction treatment regimens in multiple sclerosis. J Neurol Sci. 2009;S1:S46–S49
  133. Bar-Or A, Oger J, Gibbs E, et al. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression. Mult Scler. 2009;15:959–964
  134. Bogild M. Immunosuppression followed by immunomodulation. J Neurol Sci. 2009;(S1):S50–S54
  135. Singhal BS, Geeta S, Hundalani SG, Menon S. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting. Neurol India. 2009;57:418–423
  136. Le Page E, Comi G, Fillipi M, Edan G. Comparison of two therapeutic strategies in aggressive relapsing-remitting MS: mitoxantrone as induction for 6 months followed by interferon-β-1b versus interferon-β-1b. A 3-year randomized trial. Neurology. 2008;70:S1–A227[Abstract]
  137. Van Assche G, van Ranst M, Sciot R, Dubois B, Vermiere S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362–368
  138. Hawker K. B cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol. 2008;21:S19–S25
  139. Hartung HP. Early treatment and dose optimization BENEFIT and BEYOND. J Neurol. 2005;252(S3):S44–S50
  140. Bayas A, Rieckmann P. Managing the adverse effects of interferon beta therapy in multiple sclerosis. Drug Saf. 2000;22:149–159
  141. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354:1691–1695
  142. Ransahoff RM. “Thinking without thinking” about natalizumab and PML. J Neurol Sci. 2007;259:50–52
  143. Ellis RG, Boggild M. Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimize it?. Mult Scler. 2009;15:505–508
  144. Lebrun C, Debouverie M, Vermersch P, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler. 2008;399–405
  145. Paul F, Dorr J, Wurfel J, Vogel HP, Zipp F. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2007;78:198–200
  146. Dorr J, Bitsch A, Schmailzl KJG, et al. Severe cardiac faiure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology. 2009;73:991–993
  147. Comabella M, Martin R. Genomics in multiple sclerosis – current state and future directions. J Neuroimmunol. 2007;187:1–8
  148. Fernald GH, Knott S, Pachner A, Caillier SJ, Narayan K, Oksenberg JR, et al. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J Immunol. 2007;178:5076–5085
  149. Goertsches RH, Hecker M, Zettl UK. Monitoring of multiple sclerosis immunotherapy – from single candidates to biomarker networks. J Neurol. 2008;255:S48–S57

PII: S0303-8467(10)00144-7

doi: 10.1016/j.clineuro.2010.05.002

Clinical Neurology and Neurosurgery
Volume 112, Issue 7 , Pages 583-591 , September 2010

Article Tools